Sanibel Captiva Trust Company Inc. Sells 817 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sanibel Captiva Trust Company Inc. reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 10.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,372 shares of the medical research company’s stock after selling 817 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Edwards Lifesciences were worth $546,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Peoples Bank KS bought a new position in Edwards Lifesciences during the third quarter worth $40,000. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the fourth quarter worth $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $78.48.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,000 shares of company stock worth $2,195,180. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.77 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm’s 50-day simple moving average is $72.06 and its two-hundred day simple moving average is $71.32.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.